Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947751386> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W2947751386 abstract "e14150 Background: Over the past decade, a better understanding of cancer biology has led to a revolution in immunotherapy. Checkpoint inhibitors (ICI), bispecific antibodies and agonistic agents have shown benefit in cancer treatment. Unfortunately, not all patients benefit and, despite the advances achieved in discovering markers of response, the selection of patients can still be challenging in everyday practice. Methods: We conducted a retrospective analysis of potential prognostic and predictive factors of survival in a cohort of 186 patients enrolled into Phase I Trials testing immunotherapeutic agents at our institution. We computed univariate and multivariate analysis (MVA) of demographics, clinical and molecular characteristics to assess their prognostic and predictive potential of clinical benefit (defined as achieving Complete or Partial Response (CR/PR) as best response or disease stabilization lasting > 120 days) and survival. Molecular testing included Next Generation Sequencing (NGS - Oncomine Comprehensive Assay) grouped in DNA repair, Transcription regulation, Signal Transduction and Cell-Cell interaction pathways. Results: A total of 186 patients (Male/Female: 81/105; median age 61yo) received treatment with either immune checkpoint inhibitors (122 (65,6%)), checkpoint agonists (37 (19.9%)); bispecific antibodies (19 (10.21%) or other immunotherapies (8 (4.29%)) between November 2015 and July 2018. Royal Marsden Score (RMH) was assessed and correlated with progression free survival and overall survival in the total cohort. Median Overall Survival (mOS) was 422 days (CI95%: 345-500 days), 387 (CI95%: 297-478 days), 235 (CI95%: 131-338 days), and 167 (CI95% 64-270 days) for RMH 0, 1, 2 and 3, respectively (p = 0.007). Among 57 patients with NGS results, those with pathogenic mutations in DNA repair pathways (n = 26) showed a trend towards a higher response rate (69% vs 30% p = 0.064) and clinical benefit (65% vs 35%; p = 0.034). Conclusions: Alterations in DNA repair pathways are a potential predictor of benefit of immunotherapy and warrants further studies. A larger cohort of patients is currently being explored in our center to further validate these findings." @default.
- W2947751386 created "2019-06-07" @default.
- W2947751386 creator A5004764246 @default.
- W2947751386 creator A5007406222 @default.
- W2947751386 creator A5014120575 @default.
- W2947751386 creator A5017882861 @default.
- W2947751386 creator A5020245866 @default.
- W2947751386 creator A5029689781 @default.
- W2947751386 creator A5030334221 @default.
- W2947751386 creator A5047020634 @default.
- W2947751386 creator A5050882144 @default.
- W2947751386 creator A5056008207 @default.
- W2947751386 creator A5057848470 @default.
- W2947751386 creator A5074746574 @default.
- W2947751386 creator A5075584116 @default.
- W2947751386 creator A5080841299 @default.
- W2947751386 creator A5081566259 @default.
- W2947751386 creator A5086606713 @default.
- W2947751386 creator A5087166423 @default.
- W2947751386 date "2019-05-20" @default.
- W2947751386 modified "2023-09-26" @default.
- W2947751386 title "DNA repair pathway alterations and correlation with immunotherapy response." @default.
- W2947751386 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e14150" @default.
- W2947751386 hasPublicationYear "2019" @default.
- W2947751386 type Work @default.
- W2947751386 sameAs 2947751386 @default.
- W2947751386 citedByCount "0" @default.
- W2947751386 crossrefType "journal-article" @default.
- W2947751386 hasAuthorship W2947751386A5004764246 @default.
- W2947751386 hasAuthorship W2947751386A5007406222 @default.
- W2947751386 hasAuthorship W2947751386A5014120575 @default.
- W2947751386 hasAuthorship W2947751386A5017882861 @default.
- W2947751386 hasAuthorship W2947751386A5020245866 @default.
- W2947751386 hasAuthorship W2947751386A5029689781 @default.
- W2947751386 hasAuthorship W2947751386A5030334221 @default.
- W2947751386 hasAuthorship W2947751386A5047020634 @default.
- W2947751386 hasAuthorship W2947751386A5050882144 @default.
- W2947751386 hasAuthorship W2947751386A5056008207 @default.
- W2947751386 hasAuthorship W2947751386A5057848470 @default.
- W2947751386 hasAuthorship W2947751386A5074746574 @default.
- W2947751386 hasAuthorship W2947751386A5075584116 @default.
- W2947751386 hasAuthorship W2947751386A5080841299 @default.
- W2947751386 hasAuthorship W2947751386A5081566259 @default.
- W2947751386 hasAuthorship W2947751386A5086606713 @default.
- W2947751386 hasAuthorship W2947751386A5087166423 @default.
- W2947751386 hasConcept C117220453 @default.
- W2947751386 hasConcept C134935766 @default.
- W2947751386 hasConcept C203014093 @default.
- W2947751386 hasConcept C2524010 @default.
- W2947751386 hasConcept C2777701055 @default.
- W2947751386 hasConcept C2780674031 @default.
- W2947751386 hasConcept C33923547 @default.
- W2947751386 hasConcept C502942594 @default.
- W2947751386 hasConcept C54355233 @default.
- W2947751386 hasConcept C552990157 @default.
- W2947751386 hasConcept C71924100 @default.
- W2947751386 hasConcept C86803240 @default.
- W2947751386 hasConcept C8891405 @default.
- W2947751386 hasConceptScore W2947751386C117220453 @default.
- W2947751386 hasConceptScore W2947751386C134935766 @default.
- W2947751386 hasConceptScore W2947751386C203014093 @default.
- W2947751386 hasConceptScore W2947751386C2524010 @default.
- W2947751386 hasConceptScore W2947751386C2777701055 @default.
- W2947751386 hasConceptScore W2947751386C2780674031 @default.
- W2947751386 hasConceptScore W2947751386C33923547 @default.
- W2947751386 hasConceptScore W2947751386C502942594 @default.
- W2947751386 hasConceptScore W2947751386C54355233 @default.
- W2947751386 hasConceptScore W2947751386C552990157 @default.
- W2947751386 hasConceptScore W2947751386C71924100 @default.
- W2947751386 hasConceptScore W2947751386C86803240 @default.
- W2947751386 hasConceptScore W2947751386C8891405 @default.
- W2947751386 hasLocation W29477513861 @default.
- W2947751386 hasOpenAccess W2947751386 @default.
- W2947751386 hasPrimaryLocation W29477513861 @default.
- W2947751386 hasRelatedWork W1510442926 @default.
- W2947751386 hasRelatedWork W2189381691 @default.
- W2947751386 hasRelatedWork W2210113643 @default.
- W2947751386 hasRelatedWork W2401136278 @default.
- W2947751386 hasRelatedWork W2613990808 @default.
- W2947751386 hasRelatedWork W2752008306 @default.
- W2947751386 hasRelatedWork W2791356790 @default.
- W2947751386 hasRelatedWork W2800071778 @default.
- W2947751386 hasRelatedWork W2905679618 @default.
- W2947751386 hasRelatedWork W2943515645 @default.
- W2947751386 hasRelatedWork W2954890231 @default.
- W2947751386 hasRelatedWork W2963876800 @default.
- W2947751386 hasRelatedWork W2972535107 @default.
- W2947751386 hasRelatedWork W3008389148 @default.
- W2947751386 hasRelatedWork W3013155032 @default.
- W2947751386 hasRelatedWork W3017599093 @default.
- W2947751386 hasRelatedWork W3029687374 @default.
- W2947751386 hasRelatedWork W3131796038 @default.
- W2947751386 hasRelatedWork W3162575990 @default.
- W2947751386 hasRelatedWork W3174217249 @default.
- W2947751386 isParatext "false" @default.
- W2947751386 isRetracted "false" @default.
- W2947751386 magId "2947751386" @default.
- W2947751386 workType "article" @default.